Cecilia Radkiewicz1, Anna L V Johansson2, Paul W Dickman3, Mats Lambe4, Gustaf Edgren5. 1. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, PO Box 281, SE-171 77 Stockholm, Sweden. Electronic address: cecilia.radkiewicz@ki.se. 2. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, PO Box 281, SE-171 77 Stockholm, Sweden. Electronic address: anna.johansson@ki.se. 3. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, PO Box 281, SE-171 77 Stockholm, Sweden. Electronic address: paul.dickman@ki.se. 4. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, PO Box 281, SE-171 77 Stockholm, Sweden. Electronic address: mats.lambe@ki.se. 5. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, PO Box 281, SE-171 77 Stockholm, Sweden. Electronic address: gustaf.edgren@ki.se.
Abstract
AIM: The aim of this study is to firmly delineate temporal and age trends regarding sex discrepancies in cancer risk and survival as well as quantifying the potential gain achieved by eliminating this inequality. METHODS: We performed a population-based cohort study using data on all adult incident cancer cases (n = 872,397) recorded in the Swedish Cancer Register in 1970-2014. To assess the associations between sex and cancer risk and sex and survival, male-to-female incidence rate ratios (IRRs) and excess mortality ratios (EMRs) adjusted for age and year of diagnosis were estimated using Poisson regression. RESULTS: Men were at increased risk for 34 of 39 and had poorer prognosis for 27 of 39 cancers. Women were at increased risk for 5 of 39 and had significantly poorer survival for 2 of 39 cancers. IRRs among male predominant sites ranged from 1.05; 95% confidence interval (CI), 1.03--1.1 (lung adenocarcinoma) to 8.0; 95% CI, 7.5-8.5 (larynx). EMRs among sites with male survival disadvantage ranged from 1.1; 95% CI, 1.03-1.1 (colon) to 2.1; 95% CI, 1.5--2.8 (well-differentiated thyroid). CONCLUSION: Male sex is associated with increased risk and poorer survival for most cancer sites. Identifying and eliminating factors driving the observed sex differences may reduce the global cancer burden.
AIM: The aim of this study is to firmly delineate temporal and age trends regarding sex discrepancies in cancer risk and survival as well as quantifying the potential gain achieved by eliminating this inequality. METHODS: We performed a population-based cohort study using data on all adult incident cancer cases (n = 872,397) recorded in the Swedish Cancer Register in 1970-2014. To assess the associations between sex and cancer risk and sex and survival, male-to-female incidence rate ratios (IRRs) and excess mortality ratios (EMRs) adjusted for age and year of diagnosis were estimated using Poisson regression. RESULTS:Men were at increased risk for 34 of 39 and had poorer prognosis for 27 of 39 cancers. Women were at increased risk for 5 of 39 and had significantly poorer survival for 2 of 39 cancers. IRRs among male predominant sites ranged from 1.05; 95% confidence interval (CI), 1.03--1.1 (lung adenocarcinoma) to 8.0; 95% CI, 7.5-8.5 (larynx). EMRs among sites with male survival disadvantage ranged from 1.1; 95% CI, 1.03-1.1 (colon) to 2.1; 95% CI, 1.5--2.8 (well-differentiated thyroid). CONCLUSION: Male sex is associated with increased risk and poorer survival for most cancer sites. Identifying and eliminating factors driving the observed sex differences may reduce the global cancer burden.
Keywords:
Adult; Age distribution; Incidence; Mortality/trends; Neoplasms/epidemiology; Registries; Sex distribution; Sex factors; Survival rate; Time factors
Authors: Linda Juel Ahrenfeldt; Sören Möller; Mikael Thinggaard; Kaare Christensen; Rune Lindahl-Jacobsen Journal: Int J Public Health Date: 2019-06-24 Impact factor: 3.380
Authors: Gunnar Juliusson; Oskar Hagberg; Vladimir Lj Lazarevic; Emma Ölander; Petar Antunovic; Jörg Cammenga; Lovisa Wennström; Lars Möllgård; Mats Brune; Martin Jädersten; Stefan Deneberg; Sören Lehmann; Åsa Rangert Derolf; Martin Höglund Journal: Blood Date: 2019-10-31 Impact factor: 22.113
Authors: Ali Jalali; Kwanha Yu; Vivek Beechar; Navish A Bosquez Huerta; Anthony Grichuk; Deepika Mehra; Brittney Lozzi; Kathleen Kong; Kenneth L Scott; Ganesh Rao; Matthew N Bainbridge; Melissa L Bondy; Benjamin Deneen Journal: Cancer Res Date: 2021-03-29 Impact factor: 12.701
Authors: Mette L Johansen; L C Stetson; Vachan Vadmal; Kristin Waite; Michael E Berens; James R Connor; Justin Lathia; Joshua B Rubin; Jill S Barnholtz-Sloan Journal: Neurooncol Adv Date: 2020-01-08
Authors: Anna Cho; Helena Untersteiner; Fabian Fitschek; Farjad Khalaveh; Philip Pruckner; Noemi Pavo; Karl Rössler; Christian Dorfer; Brigitte Gatterbauer; Christoph Höller; Manuela Schmidinger; Josa M Frischer Journal: J Neurooncol Date: 2021-06-20 Impact factor: 4.130
Authors: Shehara Mendis; Seerat Anand; Joanna M Karasinska; Arvind Dasari; Joseph M Unger; Anirudh Gothwal; Lee M Ellis; Gauri Varadhachary; Scott Kopetz; Michael J Overman; Kanwal Raghav; Jonathan M Loree Journal: Oncologist Date: 2020-10-07 Impact factor: 5.837